GlassScriptPhysician profile
Faramarz Alav
NPI 1508825027
$3,280.94
in general payments reported to CMS, 2019-2025
25 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $323 · 2021: $432 · 2022: $614 · 2023: $571 · 2024: $460 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,450.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $582.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $410.31 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $252.21 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $234.97 | 2019-2024 | Farxiga |
| Amarin Pharma, INC. | $214.42 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $187.53 | 2019-2023 | Belsomra, Steglatro, Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $169.91 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $146.19 | 2024 | Xarelto |
| Mannkind Corporation | $141.18 | 2019-2022 | |
| Abbvie INC. | $140.38 | 2020-2025 | |
| Glaxosmithkline, LLC. | $139.32 | 2020-2025 | Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.65 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $104.11 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $91.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $73.89 | 2019-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.46 | 2024-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $47.85 | 2022 | |
| Pfizer INC. | $37.57 | 2023 | |
| Astellas Pharma US INC | $32.83 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.84 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $18.12 | 2023 | Gvoke Hypopen |
| Phadia US INC. | $17.18 | 2023 | Immunocap |
| Azurity Pharmaceuticals, INC. | $16.73 | 2025 | |
| Boston Scientific Corporation | $16.30 | 2023 | Wavewriter Alpha Prime 16 |
| Teva Pharmaceuticals USA, INC. | $15.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faramarz Alav listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.